Navigation Links
Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
Date:11/1/2013

SAN DIEGO, Calif., Nov. 1, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced that it will report third quarter 2013 operational results after closing of the NASDAQ Global Market on Thursday, November 7, 2013. Michael Martino, president and chief executive officer, will host a conference call to provide a business update at 5 p.m. EDT (2 p.m. PDT) on November 7, 2013.

The call will be webcast live and may be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify that you would like to join the "Ambit Third Quarter 2013 Earnings Conference Call" and reference conference ID number 35424048.
A teleconference replay will be available through Thursday, November 14, 2013.  Interested parties can access the replay by dialing 888-843-7419, or 630-652-3042 internationally, and entering the conference number 35977176.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit Biosciences website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Saturday, December 7, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.Ambit Contacts:Marcy GrahamIan Stone/David SchullExecutive Director, Investor Relations & Corp Comm 

Media ContactsAmbit Biosciences, Inc.Russo Partners858-334-2125619-308-6541/212-845-4271mgraham@ambitbio.com

ian.stone@russopartnersllc.com/david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
2. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
3. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
4. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
5. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
6. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
7. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
8. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Calithera Biosciences Secures $35 Million in Series D Financing
11. Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , April 25, 2017 Endo International plc (NASDAQ: ... May 9, 2017. Members of its senior management team will host ... at 8:30 a.m. ET. The dial-in number to ... International (678) 509-7598, and the passcode is 6086379. Please dial in ... A replay of the call will be available ...
(Date:4/20/2017)... April 20, 2017  Vivify Health, the pioneer and ... been awarded a very significant patent for the advancement ... continual care via digital health.  This landmark patent provides ... and further secures Vivify,s position as the leader in ... was the first company to apply consumer mobile devices, ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology:
(Date:4/28/2017)... Tenn. (PRWEB) , ... April 28, 2017 , ... ... system, today announced an alliance with B. Braun Medical Inc. , a leader ... role in patient care with as many as 90 percent of hospital patients receiving ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve used the same scientific ... actually works! , Countless deodorants flood the aisles that contain harmful chemicals that ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion ... this year. , The first new location will open at the corner of ... 84th and Northern Lights Drive this fall. And the third location is in the ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an innovative ... has completed a round of funding to accelerate its growth strategies. The $3.5 ... Capital is a growth equity firm focused on investments in healthcare and technology ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... describes the adoption of e-prescribing as measured in Part D Medicare data. The ... prescriptions to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced ...
Breaking Medicine News(10 mins):